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Expression of P2 microglobulin (fJ2M), a light chain of class 1 
HLA antigen, was studied in normal melanocytes and in 
benign and malignant melanocytic tumors by use of immu­
nohistochemical methods. By immunoelectron microscopy, 
normal melanocytes were shown to express P2M on the cell 
surface. In lentigo maligna melanomas and acral lentiginous 
melanomas, the mean percentages of P2M-positive tumor 
cells were significantly lower in thick (>1.50 mm) primary 
lesions and metastases than in thin (�1.50 mm) primary le­
sions. The evidence suggests that melanocyte-derived mela­
noma clones with a low grade of malignancy preserve class 1 
HLA expression, and that the clones with a high grade of 
R ecent immunohistochemical studies with monoclonal antibodies to class 1 HLA antigens have revealed that these antigens have a more-restricted tissue distribu­tion than originally supposed [1- 3]. Furthermore, it has been suggested that the malignant transformation 
of cells may be associated with changes in the expression of class 1 
HLA antigens [2,3]. The earlier immunohistochemical study of 
benign and malignant melanocytic tumors suggested that the ap­
pearance of class 1 HLA on melanocytes and nevus cells may be a 
marker for the malignant transformation of these cells [4]. How­
ever, more-recent studies have accumulated conflicting evidence 
that the malignant transformation and further neoplastic progres­
sion of melanocytes may be associated with the reduction or loss of 
class 1 HLA antigens [5-7]. In this study, we analyzed the expres­
sion of class 1 HLA antigens in normal melanocytes and in benign 
and malignant melanocytic tumors by examining the presence of 
cell surface P2 microglobulin (ft"M), which can be detected in for­
malin-fixed, paraffin-embedded sections [8]. P2M is a light chain of 
class 1 HLA antigen found in association with class 1 HLA heavy 
chain [9]. Thus, antibody against P2M reacts with class 1 HLA on the 
cell surface. 
During this investigation, we found that nevus cells in halo nevus 
express P2M strongly when associated with inflammatory infiltrate, 
while the majority of the nevus cells in common nevi do not. This 
prompted us to characterize the infiltrate in halo nevi with a panel 
of monoclonal antibodies in order to elucidate the mechanisms of 
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malignancy tend to lose the antigen expression. Nevus cells 
in common nevi have little or no expression of P2M. In halo 
nevi, however, P2M were detected on nevus cells in the le­
sions associated with inflammatory infiltration. Immunohis­
tochemical analyses of the cellular composition of the in­
flammatory cells in halo nevi demonstrated the presence of 
cytotoxic T cells together with helper/inducer T cells, Lan­
gerhans cells, and macrophages. It appears that nevus cells of 
halo nevi are destroyed by cytotoxic T cells and that class 1 
HLA antigens expressed on nevus cells play an important role 
in the target cell recognition and lysis by specific cytotoxic T 
cells.] Invest DermatoI92:243S-247S, 1989 
the spontaneous regression of halo nevus because class 1 HLA anti­
gens play an important role in the interaction between tumor cells 
and host-immune cells. 
MATERIALS AND METHODS 
Tissues The materials consisted of formalin-fixed, paraffin-em­
bedded tissues of 18 primary cutaneous melanomas (15 acral lenti­
ginous melanomas and 3 lentigo maligna melanomas), 16 meta­
static melanomas, 30 nevocellular nevi (10 junctional nevi, 10 
compound nevi, and 10 intradermal nevi), and 16 halo nevi. In 
addition, fresh specimens of one normal human femoral skin and 
five halo nevi were obtained by biopsy. The normal skin was cut 
into small pieces and immediately fixed in a periodate-lysine-para­
formaldehyde (PLP) for 4 h at 4 ° C, cryoprotected with phosphate 
buffer saline (PBS) containing 10% sucrose for 6 h, 15% sucrose 
overnight, 20% sucrose for 6 h, and finally 20% sucrose with 5% 
glycerine for 1 h at 4°C. Then, the tissue specimens were quickly 
frozen in OCT compound (Miles Scientific, Elkhart, Indiana) and 
stored at -80° C. The fresh specimens of five halo nevi were cut into 
two parts, immediately frozen in OCT compound, and kept at 
-80°C. 
Immunohistochemistry 
Light microscopy: The P2M expression in malignant melanomas, 
nevocellular nevi, and halo nevi was examined by peroxidase anti­
peroxidase (PAP) method using rabbit anti-P2M antibody. Four-mi­
crometer paraffin sections were deparaffinized in xylene and hy­
drated in graded ethanol concentrations to distilled water. After 
being soaked in methanol containing 0.5% hydrogen peroxide for 
30 min at room temperature to eliminate endogenous peroxidase 
activity, the sections were treated with 0.1 % trypsin for 10 min at 
37°C. They were incubated with normal swine serum for 30 min at 
room temperature to reduce nonspecific staining. Then, the slides 
were incubated with rabbit anti-P2M antibody (1: 400 dilution, 
DAKOPATTS, Copenhagen, Denmark) overnight at 4°C fol­
lowed by sequential 30-min incubations with swine anti-rabbit im­
munoglobulins (1: 100 dilution, DAKOPATTS) and peroxidase 
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rabbit anti-peroxidase complex ( 1: 100 dilution, DAKOPATTS) at 
room temperature. Between each step slides were rinsed with cold 
PBS. Thereafter, the sections were reacted with 0.02% 3,3'-diami­
nobenzidine tetrahydrochloride (DAB) in Tris-HCl buffer (pH7.6) 
containing 0.0 1 % hydrogen peroxide, counterstained with methyl­
green, dehydrated, and mounted. As a negative control, primary 
antiserum was replaced with non-immune normal rabbit serum at 
the same dilution. 
In cases of halo nevus with dense inflammatory infiltrate, double 
immunoenzymatic staining for P2M and S- 100 protein was per­
formed to distinguish nevus cells from inflammatory cells. After 
staining for P2M by the PAP method as described above, the sections 
were reacted with a monoclonal anti-p subunit of S- 100 protein 
(1: 400 dilution, JIMRO, Takaski, Japan) followed by biotinylated 
goat anti-mouse immunoglobulins and alkaline phosphatase-conju­
gated streptavidin (StrAviGen B-SA Kit, Biogenex Laboratories, 
San Ramon, CA). Then, staining was achieved by incubation of 
sections in naphthol AS-MX phosphate buffer (pH8.2) containing 
Fast Blue BB salt, and the sections were mounted without counter­
staining. 
For characterization of the inflammatory cells in halo nevi, 4-,um 
frozen sections were fixed with acetone for 10 min at room temper­
ature and stained with a panel of monoclonal antibodies and the 
biotin-streptavidin method, as described above. The primary mono­
clonal antibodies included Leu2a, Leu3a, Leu4, Leu7, Leu 14, 
Leu15, anti-Interleukin 2 receptor (lL-2R), anti HLA-DR (Becton 
Dickinson Immunocytometry system, Mountain View, CA), 
OKT6, OKT9, and OKM1 (Ortho Diagnostic System, Raritan, 
NJ). 
Electron microscopy: The P2M expression on normal melanocytes 
was examined by immunoelectron microscopy. Fifteen-micrometer 
frozen sections of normal human skin were mounted on poly-L-ly­
sine coated slides and air-dried. Sections were then incubated with 
monoclonal antihuman P2M antibody ( 1: 100 dilution, Becton 
Dickinson Immunocytometry System) for 2 h, sequentially with 
biotinylated goat anti-mouse immunoglobulins for 3 h, followed by 
peroxidase-conjugated streptavidin (StrAviGen B-SA kit, Biobenex 
Laboratories) for 4 h at room temperature. Between each incuba­
tion sections were rinsed with PBS containing 10% sucrose. After 
Figure 1. Immunoelectron micro­
graph of the basal layer of normal epi­
dermis. A melanocyte having no tono­
filaments (MC) stains for P2M. Positive 
staining is also seen in adjacent kerati­
nocytes. No counterstain. Bar: 1 jim. 
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refixation with 1 % glutaraldehyde solution for 5 min, the sections 
were rinsed with cold PBS and incubated in 0.02% DAB solution 
for 30 min, and then in the same solution with 0.01 % hydrogen 
peroxide for 30 min at room temperature. After washing in PBS, 
the sections were post-fixed with 2% OsO. for 1 h at room temper­
ature, rinsed with PBS, dehydrated in a graded series of ethanols, 
and embedded in epoxy resin. Unstained thin sections were exam­
ined on a Hitachi H-600 electron microscope. 
RESULTS 
Normal Melanocyte By immunoelectron microscopy, the cell 
membrane of normal melanocytes stained positively for P2M. The 
adjacent keratinocytes also stained strongly (Fig 1). 
Malignant Melanoma Table I shows the percentages of P2M 
fJositive tumor cells in 18 primary cutaneous melanomas. P2M posi­
tive cells were found 1n all but one lesion. P2M were demonstrated 
on the cell surface of almost all the tumor cells in thin melanomas 
(�1.50 mm), while in thick melanomas (> 1.50 mm) the percent­
ages of P2M positive cells decreased. In thick melanomas, however, 
the macular area adjacent to nodules usually contained many P2M 
positive cells (Fig 2). The percentages ofP2M positive cells in meta­
static melanomas are shown in Table II. P2M positive tumor cells 
were found in 15 of 16 metastatic lesions. No significant difference 
in the percentage of P2M positive cells was found between skin 
metastases and lymph-node metastases. Table III gives the mean 
percentages of P2M positive cells in thin and thick primary tumors 
and metastases. There was a significant difference in mean percent­
ages between thin primary tumors and thick primary tumors, and 
there was no significant difference between thick primary tumors 
and metastatic tumors. 
Nevocellular Nevus The majority of the nevus cells did not stain 
for P2M in all of the lesions. A small number of melanin-containing 
nevus cells in the epidermis and upper dermis stained very weakly 
for P2M in 4 junctional, 3 compound, and 3 intradermal nevi. 
Halo Nevus The nevus cells of halo nevi were easily distinguished 
from the surrounding inflammatory cells by double immunoenzy­
matic staining because of their strong blue staining for S- 100 pro­
tein. As shown in Table IV, P2M were detected on nevus cells in 13 
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Table I. Expression of P2 Microglobulin (P2M) in Primary Cutaneous Melanomas 
Patient Histologic 
Number Age/Sex Site Type 
I 76/M Face LMM' 
2 79/F Sole ALMb 
3 57/M Toe ALM 
4 67/M Toe ALM 
5 76/M Sole ALM 
6 48/M Toe ALM 
7 34/M Finger ALM 
8 75/F Sole ALM 
9 52/F Toe ALN 
10 67/M Sole ALM 
II 37/F Finger ALM 
12 54/F Sole ALM 
13 61/M Sole ALM 
14 78/F Sole ALM 
IS 67/M Scalp LMM 
16 36/F Sole ALM 
17 32/F Sole ALM 
18 76/F Face LMM 
• LMM: lentigo maligna melanoma. 
• ALM: acral lentiginous melanoma. 
of 16 lesions (Fig 3). All 13 lesions were associated with inflamma­
tory infiltration in varying degrees. The percentages of P2M positive 
cells were higher in lesions with dense infiltrates than in those with 
slight infiltrates. P2M positive cells were not detected in 3 lesions 
without inflammatory infiltration. The cellular composition of in­
flammatory infiltrates in 5 halo nevi were shown in Table V. The 
majority of the infiltrating cells were Leu4 positive T cells. Al­
though Leu3a positive helper/inducer T cells were more numerous 
than Leu2a positive suppressor/cytotoxic T cells in 3 lesions, the 
remaining 3 lesions showed a roughly equal number of both pheno­
types. The proportion of Leu 15 positive suppressor cells was always 
lower than that of Leu2a positive cells, suggesting the presence of 
Leu2a positive, Leu15 negative, cytotoxic T cells. A small number 
of IL-2R positive activated T cells and OKT9 positive proliferating 
cells were observed in all but one lesion. OKT6 positive Langerhans 
cells, OKM1 positive macrophages/null cells, and Leu7 positive 
cells were occasionally encountered. 
Figure 2. Macular area of acral lentiginous melanoma. Most of the tumor 
cells in the epidermis and papillary dermis are fl2M positive. (Peroxidase 
anti-peroxidase method, Counterstained with methylgreen.) Bar: 10 11m. 
Tumor 
Clark's Thickness Percentage of fl2M 
Level (mm) Positive Cells 
II 0.23 100 
II 0.26 90 
II 0.48 100 
II 0.70 100 
II 1.00 100 
III 0.80 100 
IV 1.62 60 
IV 2.80 30 
IV 2.80 90 
IV 3.15 70 
IV 3.32 30 
V 4.30 70 
V 5.55 70 
V 7 0 
V 8.50 30 
V 9 10 
V 10 70 
V 15 60 
Table II. Expression of P2 Microglobulin (P2M) in 
Metastatic Melanomas 
Patient Percentage of fl2M 
Number Age/Sex Site Positive Cells 
51/M Skin 20 
Skin 80 
2 76/F Lymph node 60 
3 76/F Lymph node 80 
Lymph node 90 
4 68/M Lymph node 5 
Skin 0 
5 90/M Lymph node 50 
6 87/M Lymph node 50 
7 52/F Lymph node 0 
Skin 70 
8 50/M Skin 90 
Skin 20 
9 43/M Skin 40 
Skin 90 
10 57/F Lymph node 40 
Table III. Mean Percentage of P2 Microglobulin (P2M)-Positive 
Cells in Primary and Metastatic Melanomas 
Thickness No. of Mean Percentage of 
Tumor (mm) Cases fl2M Positive Cells 
Primary, thin ;:;; 1.50 6 98.3 
Primary, thick > 1.50 12 49.2 
Metastasis 16 49.1 
Table IV. Expression of P2 Microglobulin (P2M) in Halo Nevi 
Percentage of fl2M Positive Cells 
Degree of No. of 
Infiltrate Cases 0 I+' 2+b 3+' 4+d 
None 3 3 0 0 0 0 
Slight 4 0 4 0 0 0 
Moderate 2 0 0 2 0 0 
Dense 7 0 0 I 2 4 
• 1+: 1%-24%. 
• 2+: 25%-49%. 
, 3+: 50%-74%. 
d 4+: 75%-100%. 
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Figure 3. Halo nevus associated with dense inflammatory infiltrate. Nevus 
cells show strong membrane staining for P2M as well as intracytoplasmic 
staining for p-subunit of S-l 00 protein. ( Double immunoenzymatic staining 
with peroxidase anti-peroxidase method and biotin alkaline phosphatase­
conjugated streptavidin method. No counterstain.) Bar: 10 jim. 
DISCUSSION 
The distribution of class 1 HLA antigens in benign and malignant 
melanocytic tumors was first studied by Ruiter et al [4] using mono­
clonal antibodies and the immunoperoxidase technique. They ob­
served both class 1 HLA and its light chain P2M on tumor cells in all 
of 12 primary and metastatic melanomas and 5 of 9 dysplastic nevi, 
but they could not demonstrate these antigens on almost all the 
nevus cells in most cases of nevocellular nevi. From their data, they 
suggested that class 1 HLA expression may be a marker for malig­
nant transformation of nevomelanocytes. However, they could not 
decide whether or not normal melanocytes express class 1 HLA 
because the adjacent epidermal keratinocytes stained intensely. The 
matter is still controversial at the immunoelectron microscopic 
level. Bronstein et al [10], who studied normal human skin by im­
munoelectron microscopy with a frozen section method utilizing 
the monoclonal antibody reactive with a nonpolymorphic region of 
class 1 HLA heavy chain, showed no positive staining on melano­
cytes in spite of the strong staining on keratinocytes and Langerhans 
cells. On the other hand, van Duinen et al [ 1 1], who applied several 
different immunoelectron microscopic methods, displayed positive 
staining for class 1 HLA heavy chain on normal melanocytes. In this 
study, we have indicated positive staining for P2M on normal mel a-
Table V. The Percentages of Positively Labeled Inflammatory 
Cells in Halo Nevi 
Percentage of Positive Cells 
Antibody Case 1 Case 2 Case 3 Case 4 Case 5 
Leu 4 4+' 4+ 4+ 4+ 4+ 
Leu 2a 2+b 1+' 3+d 3+ 2+ 
Leu 15 NO' rarer 1+ 1+ 1+ 
Leu 3a 3+ 4+ 3+ 3+ 2+ 
HLA-OR 3+ 3+ 3+ 4+ 4+ 
IL-2R 1+ 0 1+ 1+ rare 
OKT9 1+ 0 rare 1+ rare 
Leu 14 0 0 rare NO 1+ 
Leu 7 rare rare 1+ 0 NO 
OKT6 1+ rare 1+ 1+ 1+ 
OKMI 1+ rare rare 1+ NO 
• 4+: 75% - 100%. 
b 2+: 25%-49%. 
' 1+: 1%-24%. 
d 3+: 50%-74%. 
, NO: not done. 
r Rare: < 1%. 
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nocytes by immunoelectron microscopy and confirmed that normal 
melanocytes express both heavy and light chains of class 1 HLA 
antigens. Therefore, it is apparent that the expression of class 1 HLA 
is not a marker for malignant transformation of melanocytes. 
The expression of class 1 HLA in malignant melanomas has re­
cently been studied intensively. Brocker et al [5] and Ruiter et al [6] 
reported that the expression of class 1 HLA tends to decrease with 
increasing thickness of the primary tumor, and that class 1 HLA 
positive cells are less numerous in metastatic lesions than in primary 
tumors. Van Duinen et al [7], who assessed the prognostic signifi­
cance of class 1 HLA expression in metastatic melanomas, observed 
that the lack of expression of class 1 HLA on more than 50% of 
metastatic tumor cells correlates with the rapid death of patients. 
These authors suggested that low expression of class 1 HLA is 
associated with the progression of malignancy in malignant mela­
nomas. In our series of lentigo maligna melanomas and acral lentig­
inous melanomas, comparison of the mean percentages of P2M posi­
tive tumor cells showed a significant difference between thin 
primary tumors and thick primary tumors. However, there is no 
significant difference between thick primary tumors and metastatic 
tumors. It has been postulated that lentigo maligna melanomas and 
acral lentiginous melanomas are derived from normal melanocytes 
[12,13]. If this is the case, our results strongly suggest that melano­
cyte-derived melanoma clones with a low grade of malignancy pre­
serve P2M expression, and that the clones with a high grade of 
malignancy tend to lose the antigen expression. 
The absence of cell surface P2M does not necessarily imply the 
concomitant loss of class 1 HLA heavy chain because the dissocia­
tion of heavy chain and P2M expression has been reported in some 
premalignant and malignant lesions [ 14, 15]. However, it has been 
demonstrated that the loss of P2M leads to conformational changes 
in the class 1 HLA molecules [ 16]. Because class 1 HLA antigens 
play an important role in the interaction between neoplastic cells 
and cytotoxic T cells [17] and T-cell recognition appears to depend 
upon the configuration of class 1 HLA molecules on the tumor cell 
surface [18], the decreased expression of P2M in melanomas seems to 
be involved in the tumor growth and metastasis. 
In contrast to normal melanocytes, the majority of nevus cells in 
common nevocellular nevi did not stain for P2M, but melanin-con­
taining nevus cells in the epidermis and upper dermis sometimes 
stained weakly. The evidence indicates that the nevus cell is biologi­
cally different from the melanocyte in the expression of class 1 HLA 
antigens, although the reason is unknown. In halo nevi, however, 
nevus cells were shown to express P2M strongly in the lesions asso­
ciated with inflammatory infiltration. Furthermore, the percent­
ages of P2M positive nevus cells correlated with the degree of in­
flammatory infiltrates. Our findings are consistent with the 
observation of Bergman et al [19] and suggest that y-interferon 
derived from helper/inducer T cells induces the class 1 HLA on 
nevus cells because y-interferon is known to induce class 1 HLA 
strongly in vitro on various kinds of cultured cells including mela­
nocytes [20]. 
The view that cytotoxic T cells are responsible for the destruction 
of nevus cells in halo nevi was expressed by Micksche et al [21] and 
Mitchell et al [22], who investigated the cytotoxic effects of circu­
lating lymphocytes on cultured melanoma cells. Recently, it has 
been generally accepted that antigen-presenting cells, macrophages, 
and helper/inducer T cells participate in the induction and differen­
tiation of cytotoxic T cells [23], and that class 1 HLA molecules are 
necessary for the recognition and lysis of target cells by specific 
cytotoxic T cells [17]. Our observations have demonstrated the 
presence of cytotoxic T cells, together with Langerhans cells, mac­
rophages, and helper/inducer T cells, around the nevus cells of halo 
nevi. Taking into consideration the fact that melanoma cells and 
nevus cells of halo nevi have common tumor-associated antigens 
[24], our findings suggest that mononuclear inflammatory infiltrate 
is induced by recognizing tumor-associated antigens on nevus cells. 
Also, it appears that nevus cells are destroyed by cytotoxic T cells, 
which recognized both tumor-associated antigens and class I HLA 
antigens expressed on nevus cells. 
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